Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis

International Journal of Clinical Oncology

Volumn 19, Issue 4, 2014, Pages 693-701

  Nozawa, Masahiro ^a   Inagaki, Takeshi ^b   Nagao, Kazuhiro ^c   Nishioka, Tsukasa ^a   Komura, Takahiro ^d   Esa, Atsunobu ^e   Kitagawa, Michio ^f   Imanishi, Masaaki ^g   Uekado, Yasunari ^h   Ogawa, Takatoshi ⁱ   Kajikawa, Hiroshi ^j   Uejima, Shigeya ^k   Matsuyama, Hideyasu ^c   Hara, Isao ^b   Uemura, Hirotsugu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Naga Municipal Hospital   (Japan)

^e NTT CORPORATION   (Japan)

^f MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^g Saiseikai Tondabayashi Hospital   (Japan)

^h WAKAYAMA ROSAI HOSPITAL   (Japan)

ⁱ Kainan Municipal Hospital   (Japan)

^j Izumiotsu Municipal Hospital   (Japan)

^k KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

more..

Author keywords

Bone metastasis; Phase II; Prostate cancer; Prostate specific antigen; Skeletal related event; Zoledronic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BICALUTAMIDE; BILIRUBIN; CALCIUM; CHOLESTEROL; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GOSERELIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; POTASSIUM; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ZORADEX; ANDROGEN; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ARM WEAKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEATH; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVENT FREE SURVIVAL; FATIGUE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERTENSION; JAW OSTEONECROSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIMB PAIN; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NECK PAIN; OPEN STUDY; OVERALL SURVIVAL; PATIENT PREFERENCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PRURITUS; SIDE EFFECT; SKELETAL RELATED EVENT; SPINAL CORD COMPRESSION; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THROMBOCYTE COUNT; TIME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY; VOMITING; BLOOD; BONE NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; GOSERELIN; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84906343593     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0604-z     Document Type: Article

References (27)

1. National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer version1 2013. Available via DIALOG. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed Dec 2012
2. Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897-7903 (Pubitemid 46657388)
3. Saad F, Adachi JD, Brown JP et al (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465-5476
4. Russell RG, Watts NB, Ebetino FH et al (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759
5. Neville-Webbe HL, Gnant M, Coleman RE (2010) Potential anticancer properties of bisphosphonates. Semin Oncol 37(Suppl 1):S53-S65
6. Winter MC, Holen I, Coleman RE (2008) Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475
7. Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16:1262-1271
8. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
9. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882 (Pubitemid 38807610)
10. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
11. Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195-202 (Pubitemid 18023133)
12. Turk DC, Rudy TE, Sorkin BA (1993) Neglected topics in chronic pain treatment outcome studies: determination of success. Pain 53:3-16 (Pubitemid 23137261)
13. Kamiya N, Suzuki H, Endo T et al (2012) Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 19:169-173
14. Pummer K, Lehnert M, Stettner H et al (1997) Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32(Suppl3):81-85 (Pubitemid 27355069)
15. Fukagai T, Namiki T, Carlile RG et al (2009) Racial differences in clinical outcome after prostate cancer treatment. Methods Mol Biol 472:455-466
16. Itami Y, Yamamoto Y, Nagai Y et al (2012) Clinical outcome of stage D2 prostate cancer. Jpn J Urol 103:276
17. Gálvez R, Ribera V, González-Escalada JR et al (2008) Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis. Patient Prefer Adherence 2:215-224
18. Saad F, Eastham J (2010) Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76:1175-1181
19. Weinfurt KP, Anstrom KJ, Castel LD et al (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986-989 (Pubitemid 43778991)
20. Bamias A, Kastritis E, Bamia C (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580-8587 (Pubitemid 46211499)
21. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968-971 (Pubitemid 44023154)
22. Zervas K, Verrou E, Teleioudis Z et al (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620-623 (Pubitemid 44253605)
23. Aragon-Ching JB, Ning YM, Chen CC et al (2009) Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with antiangiogenic agents. Cancer Invest 27:221-226
24. Thumbigere-Math V, Tu L, Huckabay S et al (2012) A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol 35:386-392
25. Vahtsevanos K, Kyrgidis A, Verrou E et al (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356-5362
26. Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341-1347
27. Migliorati CA, Woo SB, Hewson I et al (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 18:1099-1106